We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monother... Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. Show more
Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm PR Newswire NEW YORK, April 26, 2024 NEW YORK, April 26, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation...
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order Canada NewsWire HAMILTON, ON and BOSTON, April 25, 2024 HAMILTON, ON and BOSTON...
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024 PR Newswire HAMILTON, ON and BOSTON...
Kuehn Law Encourages DRQ, EVBG, FREE, and FUSN Investors to Contact Law Firm PR Newswire NEW YORK, March 20, 2024 NEW YORK, March 20, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates PR Newswire HAMILTON, ON and BOSTON, March 20, 2024 Company recently...
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer PR Newswire HAMILTON, ON and BOSTON, March 19, 2024 Transaction...
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire HAMILTON, ON and BOSTON, March 6, 2024 HAMILTON, ON and BOSTON, March 6, 2024 /PRNewswire/...
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting PR Newswire HAMILTON, ON and BOSTON, March 5, 2024...
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences PR Newswire HAMILTON, ON and BOSTON, Feb. 26, 2024 HAMILTON, ON and BOSTON, Feb. 26, 2024 /PRNewswire/ -- Fusion...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.17 | 0.8 | 21.25 | 21.49 | 21.21 | 656667 | 21.38403227 | CS |
4 | 0.12 | 0.56338028169 | 21.3 | 21.55 | 20.97 | 1165914 | 21.33922636 | CS |
12 | 10.21 | 91.0793933988 | 11.21 | 21.55 | 9.09 | 2212893 | 18.46346928 | CS |
26 | 17.47 | 442.278481013 | 3.95 | 21.55 | 3.75 | 1471385 | 15.38603319 | CS |
52 | 17.72 | 478.918918919 | 3.7 | 21.55 | 2.31 | 784354 | 14.67344095 | CS |
156 | 12.92 | 152 | 8.5 | 21.55 | 1.98 | 322007 | 12.73963999 | CS |
260 | 2.92 | 15.7837837838 | 18.5 | 21.55 | 1.98 | 271121 | 12.85415138 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions